0001479290-24-000068.txt : 20240319 0001479290-24-000068.hdr.sgml : 20240319 20240319184536 ACCESSION NUMBER: 0001479290-24-000068 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240315 FILED AS OF DATE: 20240319 DATE AS OF CHANGE: 20240319 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sjuts Dustin S CENTRAL INDEX KEY: 0001796224 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 24765617 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD CITY: NEWARK STATE: CA ZIP: 94560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6157247755 MAIL ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 wk-form4_1710888327.xml FORM 4 X0508 4 2024-03-15 0 0001479290 Revance Therapeutics, Inc. RVNC 0001796224 Sjuts Dustin S C/O REVANCE THERAPEUTICS, INC 1222 DEMONBREUN STREET, 20TH FLOOR NASHVILLE TN 37203 0 1 0 0 President 0 Common Stock 2024-03-15 4 F 0 2967 5.305 D 176761 D Common Stock 2024-03-18 4 S 0 9211 5.0425 D 167550 D Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the "RSA") for 7,540 shares. The RSA vested in three equal annual installments from March 15, 2021. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units ("PSUs") granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. /s/ Dwight Moxie, Attorney-in-Fact 2024-03-19